Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials

25 Jan 2022

Abstract excerpt

The objective of this study was to characterize isolates with reduced susceptibility to cefiderocol in patients receiving cefiderocol for nosocomial pneumonia or carbapenem-resistant infections in the Phase 3 APEKS-NP and CREDIBLE-CR studies. Susceptibility testing of isolates was conducted at a central laboratory, and post-treatment changes were evaluated according to available breakpoints for cefiderocol....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotics Pharmacokinetics and Efficacy
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35076335
DOI: 10.1089/mdr.2021.0180

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical TrialsPMID 35076335Read ↗

Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE StudySemantic proximity Read ↗

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance MechanismsSemantic proximity Read ↗

Emergence of cefiderocol resistance mediated by blaAFM-1 overexpression and FptA mutations in clinical carbapenem-resistant Pseudomonas aeruginosa isolates.Semantic proximity Read ↗

Mechanisms of Cefiderocol Resistance in Carbapenemase-Producing <em>Enterobacteriaceae</em>: Insights from Comparative GenomicsSemantic proximity Read ↗

High prevalence of cefiderocol resistance in carbapenem-resistant Escherichia coli: A warning from multicenter clinical data in ChinaSemantic proximity Read ↗

Mechanisms involved in cefiderocol resistance in French <i>Pseudomonas aeruginosa</i> clinical strainsSemantic proximity Read ↗

Mechanism of action of cefiderocolSemantic proximity Read ↗

In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitalsSemantic proximity Read ↗

Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA.Semantic proximity Read ↗

In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol.Semantic proximity Read ↗

Real‑world effectiveness and safety of cefiderocol in critically ill patients with MDR Gram‑negative infections: Results from a retrospective studySemantic proximity Read ↗

Carbapenem-resistant Gram-negative bacteria exhibiting clinically undetected cefiderocol heteroresistance leads to treatment failure in a murine model of infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.